SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors aggressively position themselves for long-term AI infrastructure expansion, fueled by reports of surging server demand and high-profile partnerships. The market is closely watching the company's enterprise adoption rates and its integration into massive on-premise AI deployments, with community sentiment split between excitement over a structural growth supercycle and concerns about whether current valuation levels have moved ahead of underlying fundamentals.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is drawing significant community attention as investors debate its long-term viability, potential share dilution, and the impact of leadership disputes following a recent private placement investment. While some bulls are betting on a recovery fueled by excitement around the broader space sector and upcoming high-profile industry events, skeptics are expressing concerns over financial transparency, the lack of immediate revenue, and potential insider selling.

Telefonaktiebolaget LM Ericsson engages in the provision of telecommunications equipment and related services to mobile and fixed network operators. It operates through the following segments: Networks, Cloud Software, Services, Enterprise, and Other. The Networks segment supports all radio-access technologies and offers hardware, software and related services for both radio access and transport. The Cloud Software segment offers solutions for core networks, business and operational support systems, network design and optimization, and managed network services. The Other segment refers to the media business and other non-allocated business. Segment-level information has also been presented to Other. The company was founded by Lars Magnus Ericsson in 1876 and is headquartered in Kista, Sweden.

Telefonaktiebolaget L M Ericsson - ADR

LM Ericsson Telephone Co.

Ericsson is trending following a massive multi-year deal with AT&T to build out an open radio access network in the U.S., a development that is sparking intense discussion around its competitive positioning against Nokia. The community is actively debating the long-term implications of this contract, with many investors weighing whether this signals a major growth catalyst or if the transition to open-standard architecture will invite future margin pressure.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to the announcement of a 300 million dollar share buyback alongside recent quarterly results, which has sparked intense community discussion about the company's path toward a potential US exchange relisting. Investors are actively debating the significance of the buyback as a sign of institutional confidence versus its impact on short-term price volatility and long-term valuation.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing a parabolic price surge driven by heavy institutional momentum, derivative-linked buying, and speculation surrounding its strategic role in Nvidias new AI-focused CPU architecture. While the stock has reached all-time highs, the community remains sharply divided between investors celebrating a historic squeeze and critics highlighting extreme valuation concerns, high levels of insider selling, and the risks of a potential reversal.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant traction as investors look for indirect exposure to the highly anticipated SpaceX IPO and broader space sector growth. The community is actively debating the fund's unique portfolio, which features notable space infrastructure companies alongside a strategic allocation to SpaceX.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The Dow Jones Industrial Average is hitting record highs as the broader market finds resilience, driven by strong earnings in AI and semiconductor sectors. Despite community concerns regarding high inflation, geopolitical tensions, and consumer pessimism, investors are debating whether this momentum reflects genuine economic strength or a vulnerable, bubble-like environment.

Zoracles

Zoracles is drawing investor attention as the community debates its potential to rebound from recent market volatility, with many users highlighting the project's creator-focused ecosystem as a long-term play. Supporters are actively discussing buying opportunities during the current dip, while others are monitoring for a catalyst to drive the next sustained leg up.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant volatility following mixed phase 2 interim results for its inhaled cystic fibrosis therapy, ARCT-032, which showed mucus plug reduction but failed to meet expectations for rapid lung function improvement. While the community is actively debating whether the data represents a proof-of-concept success that warrants a longer treatment horizon or a failure to demonstrate efficacy, bulls are pointing to the company's solid cash position, CSL partnership, and the potential for better outcomes as trial doses increase.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors weigh strong prescription growth for its fibromyalgia drug against concerns over continued stock dilution and the recent approval of a reverse split authorization. Community sentiment is deeply polarized, with bulls pointing to expanding insurance coverage and institutional accumulation as signs of long-term upside, while bears express frustration over persistent share issuance and the company's historical performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EXEL A visual representation of the absurdity of this sell off. The drug that failed 1 combination trial is the blip in blue at the bottom

Jason

Shawn

RobinS

Your chart is upside down

adenosin

Victor Alan

Leslie

Matt

MMs went stop-loss fishing today after blowout earnings

StockTwits Web

StockTwits For Android 

Exelixis Inc

 A visual representation of the absurdity of this sell off. The drug that failed 1 combination trial is the blip in blue at the bottom

Chris Dupree

@cdupree should have been a 2-3$ haircut at most

@BobbyElmodo No... $EXEL was undervalued by half BEFORE this drop off. 600% quarterly revenue growth YoY with a PE of 25.

Norman Driver

 was undervalued by half BEFORE this drop off. 600% quarterly revenue growth YoY with a PE of 25.

@cdupree meant to say 2-3%, but true. Not even that. The trial failure is just a tiny, tiny fraction out of potential future revenues.

 meant to say 2-3%, but true. Not even that. The trial failure is just a tiny, tiny fraction out of potential future revenues.